title: Hypogammaglobulinemia in lung transplant recipients.
abstract: BACKGROUND
  Infectious complications continue to represent a significant source of morbidity and mortality in lung transplant recipients. Identifying specific, remediable immune defects is of potential value. After one lung transplant patient with recurrent infections was noted to be severely hypogammaglobulinemic, a screening program for humoral immune defects was instituted. The objectives were to define the prevalence of hypogammaglobulinemia in lung transplant recipients, assess levels of antibody to specific pathogens, and correlate infectious disease outcomes and survival with immunoglobulin levels.
  
  
  METHODS
  All lung transplant recipients followed at a single center between October 1996 and June 1999 underwent a posttransplant humoral immune status survey as part of routine posttransplant follow-up. This survey consists of total immunoglobulin levels (IgG, IgM, IgA), IgG subclasses (IgG1-4), and antibody titers to Pneumococcus, diphtheria, and tetanus. Since February 1997, this survey has been incorporated into the pretransplant evaluation as well. Humoral survey results for October 1996 through July 1999 were recorded, and clinical information on major infectious disease outcomes was obtained from chart reviews, discharge summaries, the Cleveland Clinic Unified Transplant Database, and review of all microbiological studies and pathology results for each patient.
  
  
  RESULTS
  Of 67 patients with humoral immune surveys drawn posttransplant, 47 (70%) had IgG levels less than 600 mg/dl (normal 717-1410 mg/dl), of which 25 (37%) had IgG levels less than 400 mg/dl ("lowest IgG group") and 22 (33%) had IgG levels between 400 and 600 mg/dl ("moderately low IgG group"). A total of 20 patients (30%) had IgG levels of more than 600 mg/dl ("normal IgG group"). Infections that were significantly more common in the lowest IgG group, and more common in the moderately low IgG group than the normal IgG group, included: number of pneumonias (P=0.0006), bacteremias (P=0.02), total bacterial infections (P=0.002), tissue-invasive cytomegalovirus (P=0.01), invasive aspergillosis (P=0.001), total fungal infections (P=0.001), and total infections (P=0.006). Median hospital days per posttransplant year was significantly different in the three groups (11.0 vs. 7.4 vs. 2.8 days, P=0.0003.) Invasive aspergillosis occurred in 44% of the lowest IgG group, 9% of the moderately low IgG group, and 0% of the normal IgG group (P<0.001). Survival was poorest in the lowest IgG group and intermediate in the moderately low IgG group. IgG subclass deficiencies occurred in a variety of patterns. Hypogammaglobulinemic patients lacked protective responses to Pneumococcus in 14/47 (30%), diphtheria in 15%, and tetanus in 19%. In a group of 48 patients screened pretransplant, 90% had normal immunoglobulin levels.
  
  
  CONCLUSIONS
  Hypogammaglobulinemia in lung transplant recipients is more common than has been previously recognized. An IgG level of less than 400 mg/dl identifies a group at extremely high risk of bacterial and fungal infections, tissue-invasive cytomegalovirus, and poorer survival. Immunoglobulin monitoring may offer an opportunity for intensive surveillance, tapering of immunosuppression, and preemptive therapy for infection.
authors.affiliation: Transplant Center and Department of Pulmonary Medicine, Cleveland Clinic Foundation, OH 44195, USA.
authors.forename: N S
authors.initials: NS
authors.lastname: Goldfarb
authors.forename: R K
authors.initials: RK
authors.lastname: Avery
authors.forename: M
authors.initials: M
authors.lastname: Goormastic
authors.forename: A C
authors.initials: AC
authors.lastname: Mehta
authors.forename: R
authors.initials: R
authors.lastname: Schilz
authors.forename: N
authors.initials: N
authors.lastname: Smedira
authors.forename: L
authors.initials: L
authors.lastname: Pien
authors.forename: M T
authors.initials: MT
authors.lastname: Haug
authors.forename: S M
authors.initials: SM
authors.lastname: Gordon
authors.forename: L K
authors.initials: LK
authors.lastname: Hague
authors.forename: J M
authors.initials: JM
authors.lastname: Dresing
authors.forename: T
authors.initials: T
authors.lastname: Evans-Walker
authors.forename: J R
authors.initials: JR
authors.lastname: Maurer
mesh_terms: D000293:Adolescent; D000328:Adult; D000361:Agammaglobulinemia / Q000150:complications* / Q000188:drug therapy; D000917:Antibody Formation; D003625:Data Collection; D005260:Female; D006801:Humans; D007136:Immunoglobulins / Q000627:therapeutic use; D016756:Immunoglobulins, Intravenous; D016040:Lung Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D013997:Time Factors
chemical_list: D007136:Immunoglobulins; D016756:Immunoglobulins, Intravenous